We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Prof
John
Geddes
Schizophrenia
This information is provided directly by researchers and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information.
Not provided at time of registration
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
01 Apr 2010
31 Dec 2012
You can take part if:
1. Diagnosis of DSM-IV schizophrenia 2. Active psychotic symptoms - i.e. hallucinations, delusions, thought disorder3. Inpatient or outpatient4. Aged 18 to 70 years. 5. Able and willing to consent to participate 6. Minimum score on PANSS 607. Drug treatment stable8. Currently taking effective dose of antipsychotic 9. Adjunctive mirtazapine appears reasonable and both investigator and patient are uncertain whether it will offer any benefit 10. Clinically appropriate to change or augment treatment. Participants for whom random allocation of folic acid or placebo is not appropriate will be allocated mirtazapine or placebo only.
Ammended 22/09/10:4. 16-70 years
You may not be able to take part if:
1. Not meeting criteria for current manic episode including schizoaffective disorder2. No antidepressant treatment within last two weeks and not considering treatment for depression 3. Not taking clozapine4. No contraindication to investigational medicinal products5. Not pregnant, breast-feeding or planning a pregnancy
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
This information has not yet been provided by the study team. You'll have an opportunity to discuss any risks and benefits that may be associated with this study prior to consenting to taking part.
Prof
John
Geddes
The study is sponsored by University of Oxford (UK) and funded by Stanley Medical Research Institute (USA).
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
for Trial ID: ISRCTN32434568
Or CPMS 9274
You can print or share the study information with your GP/healthcare provider or contact the research team directly.